Non-Opioid Pain Treatment Market Report 2025

The non-opioid pain treatment market size has grown strongly in recent years. It will grow from $50.63 billion in 2024 to $55.31 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth during the historic period can be attributed to the increasing prevalence of chronic pain, greater patient preference for safer alternatives, rising public awareness of opioid-related risks, higher demand for non-addictive treatment options, and expanded healthcare provider initiatives.

The non-opioid pain treatment market size is expected to see strong growth in the next few years. It will grow to $77.67 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The expected growth in the forecast period can be linked to increasing demand for personalized pain management, greater adoption of non-opioid therapies, a growing geriatric population, rising investment in the development of non-opioid drugs, and enhanced government support and reimbursement policies. Key trends anticipated in the forecast period include advancements in drug delivery systems, the integration of multidisciplinary care models, technology-enabled personalized medicine, progress in non-opioid pharmacological options, and innovations in patient monitoring tools.

The increasing incidence of sports-related injuries is expected to drive the growth of the non-opioid pain treatment market in the coming years. Sports-related injuries are physical injuries that occur during or as a result of sports or exercise activities. The rise in these injuries is linked to growing participation in high-intensity sports and recreational activities, which heightens the risk of physical trauma for athletes. Non-opioid pain treatment plays a crucial role in managing such injuries by providing effective pain relief and reducing inflammation without the risks associated with opioid use, enabling faster recovery, improved function, and safer long-term care. For example, in October 2024, according to Howden Group Holdings Ltd, a UK-based insurance intermediary, Europe’s top five football leagues reported 4,123 injuries during the 2023/24 season, representing a 4% increase from the previous season. As a result, the rising incidence of sports-related injuries is fueling the growth of the non-opioid pain treatment market.

Companies in the non-opioid pain treatment market are focusing on developing innovative drug formulations, such as non-opioid oral treatments, to provide effective pain relief while minimizing risks related to opioid use and addiction. Non-opioid oral treatments refer to pain-relieving drugs taken orally that do not contain opioids and work through alternative mechanisms, such as reducing inflammation, modulating nerve activity, or acting on specific receptors, to manage pain without the addiction potential or respiratory depression linked to opioids. For instance, in July 2025, Vertex Pharmaceuticals Incorporated, a US-based biotechnology firm, launched JOURNAVX, a first-in-class non-opioid therapy designed to provide effective relief for moderate-to-severe acute pain. This advanced treatment uses targeted modulation of pain pathways, features a favorable safety profile, and delivers rapid pain control, reducing dependency risks and enhancing patient outcomes. It ensures effective pain management, supports faster recovery, and improves quality of life for patients experiencing acute pain.

In May 2025, Eli Lilly and Company, a US-based pharmaceutical firm, acquired SiteOne Therapeutics Inc. for an undisclosed sum. Through this acquisition, Eli Lilly aims to strengthen its neuroscience pipeline by developing and commercializing STC-004, a non-opioid Nav1.8 inhibitor that offers a safer and effective option for chronic pain treatment without the risk of addiction. SiteOne Therapeutics Inc. is a US-based pharmaceutical company that specializes in non-opioid pain treatments.

Major players in the non-opioid pain treatment market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc, Novartis AG, GSK plc, Amgen Inc., Teva Pharmaceutical Industries Limited, Vertex Pharmaceuticals Incorporated, SUN PHARMACEUTICAL INDUSTRIES LIMITED, Perrigo Company Public Limited Company, Dr. Reddy's Laboratories, HIKMA PHARMACEUTICALS PUBLIC LIMITED COMPANY, Pacira BioSciences Inc, Heron Therapeutics Inc, AFT Pharmaceuticals Limited, Vivozon Pharmaceutical Co. Ltd, Levicept Ltd, Algiax Pharmaceuticals GmbH, Latigo Biotherapeutics Inc, Hyloris Pharmaceuticals SA.

North America was the largest region in the non-opioid pain treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in non-opioid pain treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the non-opioid pain treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

A non-opioid pain treatment refers to therapy or medication designed to manage pain without the use of opioid drugs. These treatments alleviate pain through mechanisms other than opioid receptor activation and include options such as acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), certain antidepressants, anticonvulsants for nerve-related pain, as well as physical therapies such as physiotherapy, exercise, heat or cold therapy, and massage.

The primary product types of non-opioid pain treatments include medical cannabis, menthol-based products, omega-3 fatty acid formulations, botulinum toxins, and capsaicin-derived products. Medical cannabis refers to the therapeutic use of cannabis or its extracts to manage symptoms or various health conditions. The drug classes involved in these treatments comprise NSAIDs, acetaminophen, local anesthetics, antidepressants, anticonvulsants, corticosteroids, and others, delivered via oral, topical, injectable, and other routes. These treatments are distributed through hospital pharmacies, retail pharmacies, drugstores, and mail-order pharmacies. Common applications include orthopedic and musculoskeletal pain, postoperative pain, cancer-related pain, neuropathic pain, and other conditions.

The non-opioid pain treatment market research report is one of a series of new reports that provides non-opioid pain treatment market statistics, including non-opioid pain treatment industry global market size, regional shares, competitors with a non-opioid pain treatment market share, detailed non-opioid pain treatment market segments, market trends and opportunities, and any further data you may need to thrive in the non-opioid pain treatment industry. This non-opioid pain treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-opioid pain treatment market consists of revenues earned by entities by providing services such as physical therapy services, cognitive and behavioral therapies, and interventional pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-opioid pain treatment market also includes sales of antidepressants, anticonvulsants, and acupuncture kits. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.